Could galcanezumab modulate inflammatory cytokines? A single-centre exploratory study - PubMed
5 hours ago
- #Cytokines
- #Migraine
- #Galcanezumab
- Migraine is a neurological disorder with complex pathophysiology, involving CGRP and possibly neuroinflammation.
- The study evaluated cytokine profiles in episodic migraine (EM), chronic migraine (CM), and healthy controls (HC).
- EM patients showed elevated interictal levels of IFN-γ, IL-1β, IL-6, and IL-10 compared to CM and HC.
- Galcanezumab treatment in EM patients led to a transient reduction in IFN-γ, IL-1β, IL-10, and TNF-α at Cmax (T5), but not IL-6.
- The findings suggest CGRP may influence inflammatory pathways in migraine, with galcanezumab modulating cytokine levels.
- The study was approved by the local ethics committee, and informed consent was obtained from participants.